Inflammasomes, neutrophil extracellular traps, and cholesterol

Activation of macrophage inflammasomes leads to interleukin (IL)-1β and IL-18 secretion and promotes atherosclerosis and its complications in mice and humans. However, the specific role and underlying mechanisms of the inflammasome in atherogenesis are topics of active research. Several studies in h...

Full description

Bibliographic Details
Main Authors: Alan R. Tall, Marit Westerterp
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520325839
_version_ 1818983340675432448
author Alan R. Tall
Marit Westerterp
author_facet Alan R. Tall
Marit Westerterp
author_sort Alan R. Tall
collection DOAJ
description Activation of macrophage inflammasomes leads to interleukin (IL)-1β and IL-18 secretion and promotes atherosclerosis and its complications in mice and humans. However, the specific role and underlying mechanisms of the inflammasome in atherogenesis are topics of active research. Several studies in hyperlipidemic mouse models found that the NOD-like receptor protein 3 (NLRP3) inflammasome contributes to atherosclerosis, but recent work suggests that a second hit, such as defective cholesterol efflux or accumulation of oxidized mitochondrial DNA, may be required for significant inflammasome activation. Cholesterol crystal uptake or formation in lysosomes may damage membranes and activate NLRP3 inflammasomes. Alternatively, plasma or ER membrane cholesterol accumulation may condition macrophages for inflammasome activation in the presence of danger-associated molecular patterns, such as oxidized LDL. Inflammasome activation in macrophages or neutrophils leads to gasdermin-D cleavage that induces membrane pore formation, releasing IL-1β and IL-18, and eventuating in pyroptosis or neutrophil extracellular trap formation (NETosis). In humans, inflammasome activation and NETosis may contribute to atherosclerotic plaque erosion and thrombosis, especially in patients with type 2 diabetes, chronic kidney disease, or clonal hematopoiesis. Suppression of the inflammasome by activation of cholesterol efflux or by direct inhibition of inflammasome components may benefit patients with CVD and underlying susceptibility to inflammasome activation.
first_indexed 2024-12-20T18:01:33Z
format Article
id doaj.art-77453c3d67524668a5d9d7124a040b66
institution Directory Open Access Journal
issn 0022-2275
language English
last_indexed 2024-12-20T18:01:33Z
publishDate 2019-04-01
publisher Elsevier
record_format Article
series Journal of Lipid Research
spelling doaj.art-77453c3d67524668a5d9d7124a040b662022-12-21T19:30:37ZengElsevierJournal of Lipid Research0022-22752019-04-01604721727Inflammasomes, neutrophil extracellular traps, and cholesterolAlan R. Tall0Marit Westerterp1To whom correspondence should be addressed.; Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY 10032; To whom correspondence should be addressed.To whom correspondence should be addressed.; Department of Pediatrics, Section Molecular Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; To whom correspondence should be addressed.Activation of macrophage inflammasomes leads to interleukin (IL)-1β and IL-18 secretion and promotes atherosclerosis and its complications in mice and humans. However, the specific role and underlying mechanisms of the inflammasome in atherogenesis are topics of active research. Several studies in hyperlipidemic mouse models found that the NOD-like receptor protein 3 (NLRP3) inflammasome contributes to atherosclerosis, but recent work suggests that a second hit, such as defective cholesterol efflux or accumulation of oxidized mitochondrial DNA, may be required for significant inflammasome activation. Cholesterol crystal uptake or formation in lysosomes may damage membranes and activate NLRP3 inflammasomes. Alternatively, plasma or ER membrane cholesterol accumulation may condition macrophages for inflammasome activation in the presence of danger-associated molecular patterns, such as oxidized LDL. Inflammasome activation in macrophages or neutrophils leads to gasdermin-D cleavage that induces membrane pore formation, releasing IL-1β and IL-18, and eventuating in pyroptosis or neutrophil extracellular trap formation (NETosis). In humans, inflammasome activation and NETosis may contribute to atherosclerotic plaque erosion and thrombosis, especially in patients with type 2 diabetes, chronic kidney disease, or clonal hematopoiesis. Suppression of the inflammasome by activation of cholesterol efflux or by direct inhibition of inflammasome components may benefit patients with CVD and underlying susceptibility to inflammasome activation.http://www.sciencedirect.com/science/article/pii/S0022227520325839adenosine 5′-triphosphate binding cassette transportershigh density lipoproteinoxidized lipidsatherosclerosismacrophages
spellingShingle Alan R. Tall
Marit Westerterp
Inflammasomes, neutrophil extracellular traps, and cholesterol
Journal of Lipid Research
adenosine 5′-triphosphate binding cassette transporters
high density lipoprotein
oxidized lipids
atherosclerosis
macrophages
title Inflammasomes, neutrophil extracellular traps, and cholesterol
title_full Inflammasomes, neutrophil extracellular traps, and cholesterol
title_fullStr Inflammasomes, neutrophil extracellular traps, and cholesterol
title_full_unstemmed Inflammasomes, neutrophil extracellular traps, and cholesterol
title_short Inflammasomes, neutrophil extracellular traps, and cholesterol
title_sort inflammasomes neutrophil extracellular traps and cholesterol
topic adenosine 5′-triphosphate binding cassette transporters
high density lipoprotein
oxidized lipids
atherosclerosis
macrophages
url http://www.sciencedirect.com/science/article/pii/S0022227520325839
work_keys_str_mv AT alanrtall inflammasomesneutrophilextracellulartrapsandcholesterol
AT maritwesterterp inflammasomesneutrophilextracellulartrapsandcholesterol